Guardant Health Wins $292.5 Million Verdict in False Advertising Case Against Natera

The legal battle between Guardant Health and Natera culminated in a U.S. jury awarding Guardant $292.5 million in a case that accused Natera of false advertising and unfair competition. Filed in May 2021, the lawsuit alleged that Natera made deceptive statements to promote its Signatera cancer test over Guardant's Reveal product, which is designed to detect residual and recurrent colorectal cancer[1]. A federal jury in the Northern District of California ruled in favor of Guardant, dismissing all of Natera's counterclaims and underscoring the severity of the accusations by including $175.5 million in punitive damages[2][3]. Despite the verdict, Natera expressed its intent to appeal the decision, arguing that the trial excluded critical evidence[1][3].